Trial Profile
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 12 Jul 2020 Results (n=420) from NCT01241292, NCT0139396415, NCT01441973,NCT022728038, NCT0123979718, evaluating PPK analysis of elotuzumab (including data from Japanese patients n=77) with multiple myeloma, published in the Journal of Clinical Pharmacology
- 29 Jul 2016 Status changed from active, no longer recruiting to completed.
- 19 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.